Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
Oct 29, 2024
BioXcel Therapeutics to Present at ThinkEquity ConferenceVIEW RELEASE
Oct 15, 2024
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderVIEW RELEASE
Sep 19, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Nov 06, 2024 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
0.73
CHANGE
0.0532 (7.86%)